Citation tools
"Effect of Co-administration of Ketoconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics, Safety and Tolerability of Navitoclax, a First-in-class Oral Bcl-2 Family Inhibitor, in Cancer Patients." Anticancer Research
34.4
(2014):
2001-2006.
Web. 19 April. 2024.